Vischer advises Oculis Holding, as the globally active biopharmaceutical company announced the pricing of offerings for an aggregate of 5,432,098 of its ordinary shares. The stocks value at $20.25 per unit, for total gross proceeds of USD 110
Vischer advises Oculis Holding, as the globally active biopharmaceutical company announced the pricing of offerings for an aggregate of 5,432,098 of its ordinary shares. The stocks value at $20.25 per unit, for total gross proceeds of USD 110